Good Prescribing Interventions, made an Impact in Reduced Coartem Usage – a Retrospective Study at the Copperbelt University Health Facility

K. Ponshano
{"title":"Good Prescribing Interventions, made an Impact in Reduced Coartem Usage – a Retrospective Study at the Copperbelt University Health Facility","authors":"K. Ponshano","doi":"10.19080/GJPPS.2018.05.555672","DOIUrl":null,"url":null,"abstract":"According to the WHO malaria report, 2017, it was reported in 2016 that, 91 countries had a total of 216 million cases of malaria of which malaria deaths globally reached 445,000 [1]. Malaria is the commonest presentation illness in Sub-Sahara Africa, and over diagnosis of malaria in patients presenting with fever in Zambia is a major public health problem [1-3]. Malaria remains an important cause of illness and death in adults and children. It requires an integrated approach, including prevention and prompt treatment with effective antimalarial agents [1-3]. The recommended first line treatment of malaria in Zambia is artemisin based combination (ABC) therapy that is Artemether 20mg+Lumefantrine 120mg (coartem) tablets [2]. Over the past years, the introduction of the relatively expensive artemether plus lumefantrine (Coartem) drug and the subsequent appearance of malaria resistance in our country have driven the need to rationalize the overuse of antimalarial drugs at the Copperbelt University (CBU) health facility [3]. Furthermore, the recent decline in malaria transmission in many areas of Zambia has led to increasing awareness that is often associated with neglect of non-malarial causes of fever [46]. The availability of rapid diagnostic tests for malaria (RDTs) as well as parasitological test (microscopy) has provided a potentially important instrument to address these problems. All suspected cases of fever should have malaria tests to confirm the diagnosis by using both microscopy and RDTs and supported by a quality assurance programme. In 2015 the ‘WHO Guidelines for Malaria Diagnosis and Treatment’ recommended parasitological confirmation in all patients with suspected malaria before treatment and restricting antimalarial treatment to parasite-positive patients [7,8]. This was one of the managerial interventions that were implemented at CBU health facility. The idea was to limit the over use of valuable drug to patients who may not need them but due to the presenting fever, physicians tend to prescribe even when the microscopic examination Abstract","PeriodicalId":359719,"journal":{"name":"Global Journal of Pharmacy & Pharmaceutical Sciences","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Journal of Pharmacy & Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/GJPPS.2018.05.555672","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

According to the WHO malaria report, 2017, it was reported in 2016 that, 91 countries had a total of 216 million cases of malaria of which malaria deaths globally reached 445,000 [1]. Malaria is the commonest presentation illness in Sub-Sahara Africa, and over diagnosis of malaria in patients presenting with fever in Zambia is a major public health problem [1-3]. Malaria remains an important cause of illness and death in adults and children. It requires an integrated approach, including prevention and prompt treatment with effective antimalarial agents [1-3]. The recommended first line treatment of malaria in Zambia is artemisin based combination (ABC) therapy that is Artemether 20mg+Lumefantrine 120mg (coartem) tablets [2]. Over the past years, the introduction of the relatively expensive artemether plus lumefantrine (Coartem) drug and the subsequent appearance of malaria resistance in our country have driven the need to rationalize the overuse of antimalarial drugs at the Copperbelt University (CBU) health facility [3]. Furthermore, the recent decline in malaria transmission in many areas of Zambia has led to increasing awareness that is often associated with neglect of non-malarial causes of fever [46]. The availability of rapid diagnostic tests for malaria (RDTs) as well as parasitological test (microscopy) has provided a potentially important instrument to address these problems. All suspected cases of fever should have malaria tests to confirm the diagnosis by using both microscopy and RDTs and supported by a quality assurance programme. In 2015 the ‘WHO Guidelines for Malaria Diagnosis and Treatment’ recommended parasitological confirmation in all patients with suspected malaria before treatment and restricting antimalarial treatment to parasite-positive patients [7,8]. This was one of the managerial interventions that were implemented at CBU health facility. The idea was to limit the over use of valuable drug to patients who may not need them but due to the presenting fever, physicians tend to prescribe even when the microscopic examination Abstract
良好的处方干预措施对减少复方蒿甲醚的使用产生了影响——铜带大学卫生设施的回顾性研究
根据世卫组织《2017年疟疾报告》,据报道,2016年,全球91个国家共有2.16亿疟疾病例,其中疟疾死亡人数达44.5万人[1]。疟疾是撒哈拉以南非洲地区最常见的表现疾病,在赞比亚,发烧患者中疟疾的过度诊断是一个主要的公共卫生问题[1-3]。疟疾仍然是成人和儿童患病和死亡的一个重要原因。它需要一种综合方法,包括预防和及时使用有效的抗疟药物进行治疗[1-3]。赞比亚推荐的疟疾一线治疗是青蒿素联合治疗(ABC),即蒿甲醚20mg+甲苯曲明120mg(复方蒿甲醚)片[2]。在过去的几年里,相对昂贵的蒿甲醚加甲苯胺(复方蒿甲醚)药物的引入,以及随后在我国出现的疟疾耐药性,促使了对铜带大学(CBU)卫生机构过度使用抗疟药物进行合理化的需要[3]。此外,最近赞比亚许多地区疟疾传播的下降导致人们意识的提高,而这往往与忽视发烧的非疟疾原因有关[46]。疟疾快速诊断测试以及寄生虫学测试(显微镜)的可用性为解决这些问题提供了一个潜在的重要工具。所有发热疑似病例都应进行疟疾检测,通过使用显微镜和快速诊断试验确认诊断,并得到质量保证规划的支持。2015年,《世卫组织疟疾诊断和治疗指南》建议在治疗前对所有疑似疟疾患者进行寄生虫学确认,并将抗疟治疗仅限于寄生虫阳性患者[7,8]。这是在CBU卫生设施实施的管理干预措施之一。这个想法是为了限制过度使用有价值的药物,病人可能不需要他们,但由于呈现发烧,医生倾向于开处方,即使显微镜检查摘要
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信